Open Orphan plc announced that hVIVO, a subsidiary of Open Orphan, has been awarded a new study with an existing Big Pharma client to act as a vaccination site for a Phase II field study of the client's respiratory syncytial virus (RSV) vaccine candidate. As part of the study, hVIVO will recruit 60 healthy volunteers to the Company's new site clinic at Plumbers Row, where they will then be inoculated with either the RSV vaccine candidate or a placebo. As opposed to a human challenge study, where volunteers would then be challenged and quarantined within hVIVO's FluCamp facilities, these participants will then be free to leave the facilities.

Participants will then be monitored for RSV symptoms over the following months, with regular clinical check-ups at Plumbers Row, to assess the efficacy of the vaccine candidate and its ability to prevent illness through RSV. The study is expected to begin in Third Quarter 2022 with the majority of revenue from the contract recognised in 2023. This is the first vaccine field study the Company has been awarded since it announced the expansion of its facilities on 8 March 2022.

In addition to the core human challenge studies the expansion has enabled Open Orphan to provide a larger service offering including non-first in human Phase I trials such as PK (pharmacokinetics) studies, bridging studies and Phase II trials in patients and healthy volunteers. The volunteers for the study will be recruited through the Company's specialist volunteer recruitment arm, FluCamp. FluCamp has decades of experience attracting suitable healthy subjects to meet recruitment requirements, primarily sourcing subjects for hVIVO trials to date.

FluCamp's large database, tech-enabled platform and recently improved screening capabilities will mean that hVIVO is able to efficiently recruit and assess potential volunteers for its client's field studies in a timely and cost-effective manner.